Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex99d1.htm |
| EX-10.4 - EX-10.4 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex10d4.htm |
| EX-10.3 - EX-10.3 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex10d3.htm |
| EX-10.2 - EX-10.2 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex10d2.htm |
| EX-10.1 - EX-10.1 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex10d1.htm |
| EX-3.2 - EX-3.2 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex3d2.htm |
| EX-3.1 - EX-3.1 - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_1ex3d1.htm |
| 8-K - 8-K - MADRIGAL PHARMACEUTICALS, INC. | a16-15258_18k.htm |
Exhibit 16.1
July 22, 2016
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated July 22, 2016, of Madrigal Pharmaceuticals, Inc. (formerly known as “Synta Pharmaceuticals Corp.”) and are in agreement with the statements contained in the second, third and fourth paragraphs therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP